leisure time
As a boy growing up with hemophilia A, Noah Frederick reserved the end of his annual checkups to talk about new technologies. His doctor walked through various experimental approaches for the bleeding disorder and, invariably, gene therapy. It was coming, he always said, in your lifetime.
Last year, it finally arrived. But Frederick, now a 23-year-old software engineer, isn’t sure he’ll get it. He wants to be part of the sci-fi future gene therapy has always represented, but a recent doctor’s visit left him uncertain.
advertisement
“I’m on the fence,” he said.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Senate panel eyes new effort on drug shortages
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
